Medical News

RSS

Seven abstracts on Lantheus' PET imaging candidates to be presented at ASNC2010

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced that seven abstracts related to two of the company's cardiac Positron Emission Tomography (PET) imaging candidates will be presented at ASNC2010, the 15th Annual Scientific Session of the American Society of Nuclear Cardiology, being held September 23-26, 2010 in Philadelphia.

20 Sep 2010

St. Jude Medical granted European CE Mark for Athena deep brain stimulation therapy management system

St. Jude Medical, Inc., a global medical device company, today announced European CE Mark approval of its new Athena™ programmer, a deep brain stimulation (DBS) therapy management system. This next-generation platform offers clinicians a powerful yet easy-to-use interface that enables them to set or adjust therapeutic parameters to optimize patient results.

20 Sep 2010

Celldex commences CDX-011 Phase 2b trial in advanced breast cancer patients expressing GPNMB

Celldex Therapeutics, Inc. today announced that the first patient has been treated in a randomized Phase 2b study of the Company's CDX-011 (glembatumumab vedotin) antibody drug conjugate in glycoprotein NMB (GPNMB) expressing advanced, refractory breast cancer patients. CDX-011 targets the protein GPNMB, which is over expressed in a variety of cancers including breast cancer, melanoma, and brain tumors.

20 Sep 2010

Boston Scientific announces acquisition of Asthmatx

Boston Scientific Corporation today announced the signing of a definitive merger agreement, under which Boston Scientific will acquire Asthmatx, Inc., a privately held company in Sunnyvale, California. Asthmatx designs, manufactures and markets a less-invasive, catheter-based bronchial thermoplasty procedure for the treatment of severe persistent asthma in the 6 to 8 million patients 18 years and older worldwide whose asthma is not well controlled with drugs (inhaled medications).

20 Sep 2010

Facts about air travel for individuals with special needs

September and October, the traditional "shoulder season" between summer's high season and winter's low season, are good months for slow walkers and individuals with special needs to travel. There are fewer tourists overall, meaning more space on walkways and fewer lines for museums and other attractions. Prices drop, too, especially for international destinations.

20 Sep 2010

Walmart, CVS to sell NEW Handheld Power Pill Grinder for dysphagia patients

Variant Products Ltd. announced today that walmart.com and cvs.com will soon be selling its NEW Handheld Power Pill Grinder. It is significant because sales velocities are being closely monitored by both retailers for store consideration. Validating the market, Walmart and CVS currently dedicate resources to educate and address dysphagia concerns (difficulty swallowing). People who struggle with this issue often crush or grind their meds/supplements and the Power Pill Grinder offers a unique alternative to traditional manual crushers.

20 Sep 2010

Cintas launches new comprehensive safe floor program

Cintas Corporation today launched its new comprehensive safe floor program. Developed to provide a cost-effective solution for protecting and maintaining floors on a daily basis, the program enables businesses to maximize the life of flooring while improving safety and image. Its mats are designed to capture contaminants and moisture before they are tracked through a facility, while Cintas' services remove them in order to reduce slips and falls.

20 Sep 2010

Nano Israel 2010 Conference to focus on Innovations and Business Opportunities

The Nano Israel 2010 Conference and the Exhibition accompanying will be held on November the 8th and the 9th in the Dan Panorama Hotel, Tel Aviv. The event will focus on Innovations and Business Opportunities in the energy, water, environment, nano-material, nano-electronics, nano-photonics, nano-bio and nano-medicine fields.

20 Sep 2010

Scientific update conference on Lyme and Tick-Borne Diseases

Lyme disease is a growing threat in the U.S., with numbers that continue to rise despite increased awareness about the disease. "Little is being done to stop the spread of Lyme disease and to help those who are suffering from chronic Lyme," says Pat Smith, president of the all-volunteer national Lyme Disease Association, which funds research, educates the public, and provides scientific conferences for doctors.

20 Sep 2010

Clerity achieves ISO 9001:2008 Quality Management Certification

Clerity, a full-service provider of mainframe migration, modernization, and optimization solutions, today announced that it has received ISO 9001:2008 Quality Management Certification. This independent certification validates Clerity's adherence to documented processes and procedures while delivering high-quality, global system integration solutions.

20 Sep 2010

APAF selects AB SCIEX TripleTOF 5600 System to help advance proteomics research

AB SCIEX, a global leader in life science analytical technologies, today announced that the Australian Proteome Analysis Facility has chosen the AB SCIEX TripleTOF 5600 System to help advance proteomics research by significantly expanding proteome coverage. The TripleTOF 5600 System is the life science industry's fastest and most sensitive high-resolution mass spectrometer for high-performance qualitative and quantitative analysis.

20 Sep 2010

Aradigm Corporation closes transaction with Novo Nordisk A/S

Aradigm Corporation today announced that it closed the transaction contemplated by the previously announced July 30, 2010 Stock Purchase Agreement with Novo Nordisk A/S. At the closing, the Company issued 26 million shares of the Company's common stock to Novo Nordisk A/S in a private placement as consideration for the termination of a promissory note in favor of Novo Nordisk A/S under which approximately $9.1 million was outstanding on July 30, 2010, representing an effective price per share of $0.3505.

20 Sep 2010

Abbott to commercialize Celera's CE-marked KIF6 genotyping assay outside U.S.

Celera Corporation and Abbott today announced that they have signed an exclusive distribution agreement to market Celera's CE-marked KIF6 diagnostic test for use on Abbott's CE-marked m2000™ instrument system. The KIF6 genotyping assay detects a genetic marker that may be used in conjunction with clinical evaluation and patient assessment for the identification of individuals at risk for coronary heart disease (CHD), and in patients for whom statin treatment is being considered.

20 Sep 2010

ICF International awarded re-compete contract to provide IT, scientific support services to NCTR

ICF International, a leading provider of consulting services and technology solutions to government and commercial clients, has been awarded a $31.8 million re-compete contract by the U.S. Food and Drug Administration to provide information technology and scientific support services to the National Center for Toxicological Research.

20 Sep 2010

Micromet initiates MT103 phase 2 trial in adult ALL patients

Micromet, Inc. today announced the initiation of a phase 2 trial of the Company's lead product candidate blinatumomab (MT103) in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL). Blinatumomab is the first of a new class of agents called BiTE antibodies, designed to harness the body's T cells to kill cancer cells.

20 Sep 2010

$Neovasc commences enrollment in Reducer trial for refractory angina$

Neovasc commences enrollment in Reducer trial for refractory angina

Neovasc Inc., a developer of novel technologies used to treat vascular disease, today announced that the first patients have been enrolled in its COSIRA trial designed to assess the clinical efficacy of the Neovasc Reducer(TM) product for the treatment of refractory angina. The COSIRA (Coronary Sinus Reducer for Treatment of Refractory Angina) trial is a multicenter, sham-controlled, randomized, double-blinded study of the Reducer that is expected to enroll up to 124 patients.

20 Sep 2010

LifePoint Hospitals intends to sell private offering of Senior Notes due 2020

LifePoint Hospitals, Inc. announced today its intention to sell through a private offering $400 million in aggregate principal amount of Senior Notes due 2020. The Notes will be senior unsecured obligations of the Company and will be guaranteed by substantially all of the Company's subsidiaries that guarantee its senior secured credit facilities.

20 Sep 2010

Hatch Medical signs agreement with Majid Shano to broker super-elastic orthopedic stapling technology

Hatch Medical, L.L.C., a medical device incubator and technology brokerage firm, announced today that it has recently entered into an agreement with Majid Shano MB, B.CH., (Munich, Germany) to broker his patented, super-elastic orthopedic stapling technology.

20 Sep 2010

Chronix Biomedical completes Series E financing

Chronix Biomedical today announced that it has completed a Series E financing that raised $1.8 million from existing and new investors. Chronix is developing disease-specific biomarkers based on DNA fragments that are released into the bloodstream by damaged and dying (apoptotic) cells. Chronix's serum DNA biomarkers are applicable to a wide range of cancers and other chronic diseases.

20 Sep 2010

First Edition: September 20, 2010

Today's headlines include news about the political positioning of both Democrats and Republicans on health reform, the mid-term elections and GOP plans to repeal and replace.

20 Sep 2010